Literature DB >> 35122587

The adenosine-A2a receptor regulates the radioresistance of gastric cancer via PI3K-AKT-mTOR pathway.

Guihong Liu1,2, Song Yang1,2, Yang Liu2, Yumei Xu1, Hui Qiu1, Jian Sun1,2, Jun Song3,4, Linsen Shi5.   

Abstract

BACKGROUND: Radiotherapy is a key strategy in gastric cancer (GC) treatment. However, radioresistance remains a serious concern. It is unclear whether the accumulation of adenosine A2a receptor (ADO-A2aR) is related to radioresistance in GC. In this study, the molecular role of ADO-A2aR in GC radioresistance was investigated.
METHODS: Colony formation assays were used to assess the role of ADO-A2aR on radioresistance. GC stem cell surface marker expression (including Nanog, OCT-4, SOX-2 and CD44) and PI3K/AKT/mTOR signaling pathway associated protein levels (including phosphorylated PI3K, phosphorylated AKT and phosphorylated mTOR) were determined via western blotting, flow cytometry and immunofluorescence. In addition, the role of ADO-A2aR on radioresistance was explored in vivo using murine xenograft models.
RESULTS: ADO-A2aR regulated GC cell stemness both in vitro and in vivo. This was shown to induce radioresistance in GC. ADO-A2aR was revealed to significantly induce cell cycle arrest and promote GC cell apoptosis. These activities were closely linked to activation of the PI3K/AKT/mTOR pathway.
CONCLUSION: This study identified that ADO enhances GC cell stemness via interaction with A2aR and subsequent activation of the PI3K/AKT/mTOR pathway. Ultimately, this resulted in radioresistance. A2aR is a potential target to improve GC radiosensitivity.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Adenosine; Adenosine-A2a receptor; Gastric cancer; PI3K/AKT/mTOR; Radioresistance

Mesh:

Substances:

Year:  2022        PMID: 35122587     DOI: 10.1007/s10147-022-02123-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

1.  PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.

Authors:  Jiezhong Chen; Renfu Shao; Feng Li; Michael Monteiro; Jun-Ping Liu; Zhi Ping Xu; Wenyi Gu
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-12       Impact factor: 2.557

2.  Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.

Authors:  Nathan Tonlaar; Sandra Galoforo; Bryan J Thibodeau; Samreen Ahmed; Thomas G Wilson; Paola Yumpo Cardenas; Brian Marples; George D Wilson
Journal:  Radiother Oncol       Date:  2017-08-16       Impact factor: 6.280

Review 3.  Targeting the adenosine pathway for cancer immunotherapy.

Authors:  Akil Hammami; David Allard; Bertrand Allard; John Stagg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 4.  Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.

Authors:  Lei Chang; Peter H Graham; Jie Ni; Jingli Hao; Joseph Bucci; Paul J Cozzi; Yong Li
Journal:  Crit Rev Oncol Hematol       Date:  2015-07-18       Impact factor: 6.312

5.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 6.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.

Authors:  Gennady G Yegutkin
Journal:  Biochim Biophys Acta       Date:  2008-02-12

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment.

Authors:  Jie Lan; Haiquan Lu; Debangshu Samanta; Shaima Salman; You Lu; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-21       Impact factor: 12.779

9.  Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo.

Authors:  Chih-Chia Yu; Shih-Kai Hung; Hon-Yi Lin; Wen-Yen Chiou; Moon-Sing Lee; Hui-Fen Liao; Hsien-Bin Huang; Hsu-Chueh Ho; Yu-Chieh Su
Journal:  Oncotarget       Date:  2017-08-02

Review 10.  Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.

Authors:  Ziwen Wang; Yujung Huang; Jiqiang Zhang
Journal:  Cell Mol Biol Lett       Date:  2014-04-11       Impact factor: 5.787

View more
  2 in total

Review 1.  Emerging roles of purinergic signaling in anti-cancer therapy resistance.

Authors:  Michele Zanoni; Anna Pegoraro; Elena Adinolfi; Elena De Marchi
Journal:  Front Cell Dev Biol       Date:  2022-09-19

Review 2.  Adenosine signaling: Optimal target for gastric cancer immunotherapy.

Authors:  Junqing Wang; Linyong Du; Xiangjian Chen
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.